Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.10 +2.44%
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $10 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
